Form 4: Oruka Therapeutics General Counsel Acquires Stock Options

Oruka Therapeutics' General Counsel, Paul T. Quinlan, has acquired 162,500 stock options, vesting monthly from January 1, 2025.

Summary

• Paul T. Quinlan, the General Counsel of Oruka Therapeutics, has reported the acquisition of 162,500 employee stock options.
• The options have an exercise price of $12.50.
• These options vest monthly, with 1/48th of the shares vesting each month starting from January 1, 2025.
• The options expire on January 21, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a key executive, which is generally a positive sign of alignment between management and shareholders. It is not a major event but is a positive indicator.

Positives

• The acquisition of stock options by a key executive like the General Counsel can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for reporting changes in beneficial ownership by company insiders. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with those of shareholders.
• The vesting schedule of 1/48th monthly is a typical vesting schedule for employee stock options.

Stakeholder Impact

• The stock option grant aligns the General Counsel's interests with those of shareholders, potentially encouraging value creation.

Key Dates

Keywords

stock options, insider trading, executive compensation, Oruka Therapeutics, General Counsel, Paul T. Quinlan